LONG-TERM SAFETY AND EFFICACY OF CERTOLIZUMAB PEGOL IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS, INCLUDING ANKYLOSING SPONDYLITIS AND NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: 96-WEEK OUTCOMES OF THE RAPID-AXSPA TRIAL

被引：1

作者：

Sieper, J. ^{[1
]}

Rudwaleit, M. ^{[2
]}

van der Heijde, D. ^{[3
]}

Maksymowych, W. ^{[4
]}

Dougados, M. ^{[5
]}

Mease, P. J. ^{[6
,7
]}

Braun, J. ^{[8
]}

Deodhar, A. ^{[9
]}

Hoepken, B. ^{[10
]}

Nurminen, T. ^{[10
]}

Landewe, R. ^{[11
,12
]}

机构：

[1] Univ Hosp Charite, Rheumatol Dept, Berlin, Germany

[2] Endokrinologikum Berlin, Berlin, Germany

[3] Leiden Univ, Med Ctr, Dept Rheumatol, Leiden, Netherlands

[4] Univ Alberta, Dept Med, Edmonton, AB, Canada

[5] Cochin Hosp, Dept Rheumatol, Paris, France

[6] Swedish Med Ctr, Seattle, WA USA

[7] Univ Washington, Seattle, WA 98195 USA

[8] Rheumazentrum Ruhrgebiet, Herne, Germany

[9] Oregon Hlth & Sci Univ, Portland, OR 97201 USA

[10] UCB Pharma, Monheim, Germany

[11] Univ Amsterdam, Acad Med Ctr, NL-1105 AZ Amsterdam, Netherlands

[12] Atrium Med Ctr, Heerlen, Netherlands

来源：

ANNALS OF THE RHEUMATIC DISEASES | 2014年 / 73卷

关键词：

D O I：

10.1136/annrheumdis-2014-eular.1636

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

SAT0351

引用

页码：719 / 720

页数：2

共 50 条

[1] LONG-TERM SAFETY AND EFFICACY OF CERTOLIZUMAB PEGOL IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS: 96-WEEK OUTCOMES OF THE RAPID-AXSPA TRIAL
Sieper, J.
Rudwaleit, M.
van der Heijde, D.
Maksymowych, W. P.
Dougados, M.
Mease, P. J.
Reveille, J.
Braun, J.
Deodhar, A.
Arledge, T.
Nurminen, T.
Landewe, R.
[J]. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2014, 32 (05) : 785 - 786
[2] LONG-TERM MAINTENANCE OF IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES WITH CERTOLIZUMAB PEGOL IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS, INCLUDING ANKYLOSING SPONDYLITIS AND NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: 96-WEEK RESULTS OF THE RAPID-AXSPA STUDY
Sieper, J.
Kivitz, A.
van Tubergen, A.
Deodhar, A.
Szegvari, B.
Nurminen, T.
Landewe, R.
[J]. VALUE IN HEALTH, 2014, 17 (07) : A385 - A385
[3] EFFECT OF CERTOLIZUMAB PEGOL ON SIGNS AND SYMPTOMS OF AXIAL SPONDYLOARTHRITIS, INCLUDING ANKYLOSING SPONDYLITIS AND NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: 24-WEEK RESULTS OF RAPID-AXSPA STUDY
Landewe, R.
Rudwaleit, M.
van der Heijde, D.
Dougados, M.
Maksymowych, W. P.
Braun, J.
Deodhar, A.
Stach, C.
Hoepken, B.
Coteur, G.
Kielar, D.
Fichtner, A.
Arledge, T.
Sieper, J.
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 86 - 87
[4] Safety and Efficacy of Certolizumab Pegol over 96 Weeks in Patients with Axial Spondyloarthritis, Including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis.
Sieper, Joachim
Rudwaleit, Martin
van der Heijde, Desiree M.
Maksymowych, Walter P.
Dougados, Maxime
Mease, Philip
Braun, Juergen
Deodhar, Atul A.
Hoepken, Bengt
Nurminen, Tommi
Landewe, Robert B. M.
[J]. ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S376 - S377
[5] LONG-TERM MAINTENANCE OF IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES WITH CERTOLIZUMAB PEGOL IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS, INCLUDING ANKYLOSING SPONDYLITIS AND NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: 48-WEEK RESULTS OF THE RAPID-AXSPA STUDY
Sieper, J.
Kivitz, A.
van Tubergen, A.
Deodhar, A.
Coteur, G.
Singh, P.
Landewe, R.
[J]. VALUE IN HEALTH, 2013, 16 (07) : A569 - A569
[6] Safety and Efficacy of Certolizumab Pegol over 204 Weeks in Patients with Axial Spondyloarthritis, Including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis
Deodhar, Atul A.
Dougados, Maxime
Landewe, Robert
Sieper, Joachim
Maksymowych, Walter
Rudwaleit, Martin
van Den Bosch, Filip
Braun, Juergen
Mease, Philip J.
Kivitz, Alan
Walsh, Jessica
Davies, Owen
Hoepken, Bengt
Peterson, Luke
van der Heijde, Desiree
[J]. ARTHRITIS & RHEUMATOLOGY, 2016, 68
[7] CERTOLIZUMAB PEGOL IS ASSOCIATED WITH LONG-TERM IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES IN AXIAL SPONDYLOARTHRITIS PATIENTS, INCLUDING ANKYLOSING SPONDYLITIS AND NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: 4-YEAR OUTCOMES FROM THE RAPID-AXSPA STUDY
Sieper, J.
Kivitz, A.
van Tubergen, A.
Deodhar, A.
Harris, K.
Nurminen, T.
Landewe, R.
[J]. VALUE IN HEALTH, 2016, 19 (07) : A595 - A595
[8] CONTINUED IMPROVEMENTS IN WORKPLACE AND HOUSEHOLD PRODUCTIVITY WITH CERTOLIZUMAB PEGOL TREATMENT IN AXIAL SPONDYLOARTHRITIS, INCLUDING ANKYLOSING SPONDYLITIS AND NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: 48-WEEK RESULTS FROM THE RAPID-AXSPA STUDY
van der Heijde, D.
Braun, J.
Rudwaleit, M.
Purcaru, O.
Kavanaugh, A.
[J]. VALUE IN HEALTH, 2013, 16 (07) : A570 - A570
[9] Four Year Imaging Outcomes in Patients with Axial Spondyloarthritis Treated with Certolizumab Pegol, Including Patients with Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis
van der Heijde, Desiree
Baraliakos, Xenofon
Hermann, Kay-Geert
Landewe, Robert
Machado, Pedro
Maksymowych, Walter
Davies, Owen
de Peyrecave, Natasha
Hoepken, Bengt
Bauer, Lars
Nurminen, Tommi
Braun, Juergen
[J]. ARTHRITIS & RHEUMATOLOGY, 2016, 68
[10] Effect Of Certolizumab Pegol Over 48 Weeks In Patients With Axial Spondyloarthritis, Including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis
Landewe, Robert B. M.
Rudwaleit, Martin
van der Heijde, Desiree M.
Dougados, Maxime
Mease, Philip J.
Reveille, John D.
Walsh, Jessica
Kivitz, Alan J.
Maksymowych, Walter P.
Braun, Juergen
Deodhar, Atul A.
Stach, Christian
Hoepken, Bengt
Singh, Pritibha
Sieper, Joachim
[J]. ARTHRITIS AND RHEUMATISM, 2013, 65 : S767 - S767

← 1 2 3 4 5 →